Published October 21, 2022 | Version Supplemental Material
Journal Article Open

Photoswitchable Isoprenoid Lipids Enable Optical Control of Peptide Lipidation

  • 1. ROR icon University of California, San Francisco
  • 2. ROR icon California Institute of Technology
  • 3. ROR icon University of Minnesota
  • 4. ROR icon Purdue University West Lafayette
  • 5. ROR icon New York University
  • 6. ROR icon Syracuse University
  • 7. ROR icon University of Pennsylvania

Abstract

Photoswitchable lipids have emerged as attractive tools for the optical control of lipid bioactivity, metabolism, and biophysical properties. Their design is typically based on the incorporation of an azobenzene photoswitch into the hydrophobic lipid tail, which can be switched between its trans- and cis-form using two different wavelengths of light. While glycero- and sphingolipids have been successfully designed to be photoswitchable, isoprenoid lipids have not yet been investigated. Herein, we describe the development of photoswitchable analogs of an isoprenoid lipid and systematically assess their potential for the optical control of various steps in the isoprenylation processing pathway of CaaX proteins in Saccharomyces cerevisiae. One photoswitchable analog of farnesyl diphosphate (AzoFPP-1) allowed effective optical control of substrate prenylation by farnesyltransferase. The subsequent steps of isoprenylation processing (proteolysis by either Ste24 or Rce1 and carboxyl methylation by Ste14) were less affected by photoisomerization of the group introduced into the lipid moiety of the substrate a-factor, a mating pheromone from yeast. We assessed both proteolysis and methylation of the a-factor analogs in vitro and the bioactivity of a fully processed a-factor analog containing the photoswitch, exogenously added to cognate yeast cells. Combined, these data describe the first successful conversion of an isoprenoid lipid into a photolipid and suggest the utility of this approach for the optical control of protein prenylation.

Copyright and License

Copyright © 2022 American Chemical Society

Acknowledgement

J.M., T.B., and A.L.C. contributed equally. J.M., T.B., A.L.C., J.S., and S.A. performed experiments. J.M., T.B., A.L.C., J.S., and S.A. analyzed data. J.M., C.A.H., D.H.T., and M.D.D. conceived the study. J.L.H., C.A.H., D.H.T., and M.D.D. supervised the study. J.M. wrote the first draft. T.B., A.L.C., C.A.H., D.H.T., and M.D.D. revised the manuscript. All authors commented on the manuscript.

Additional Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acschembio.2c00645.

  • Supplementary Figures, experimental procedures and compound characterization including 1H NMR, 13C NMR, and 31P NMR spectra and HPLC chromatograms (PDF)

Files

cb2c00645_si_001.pdf

Files (2.3 MB)

Name Size Download all
md5:833a779d5a217b4c91aa85e7d69398a6
2.3 MB Preview Download

Additional details

Identifiers

ISSN
1554-8937

Related works

Funding

Division of Chemistry
NSF/CHE 1905204
National Cancer Institute
K00CA253758
National Institute of Neurological Disorders and Stroke
R01NS108151
National Institute of General Medical Sciences
R01GM132606

Dates

Available
2022-10-04
Published online

Caltech Custom Metadata

Publication Status
Published